Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson’s disease

References

• De Virgilio A, Greco A, Fabbrini G, et al. Parkinson’s disease: autoimmunity and neuroinflammation. Autoimmun Rev. 2016;15(10):1005–1011. doi:10.1016/j.autrev.2016.07.02227497913
   PubMed Web of Science ®Google Scholar
• González-Casacuberta I, Juárez-Flores DL, Morén C, Garrabou G. Bioenergetics and autophagic imbalance in patients-derived cell models of parkinson disease supports systemic dysfunction in neurodegeneration. Front Neurosci. 2019;13:894. doi:10.3389/fnins.2019.0089431551675
   PubMed Web of Science ®Google Scholar
• Vila M, Przedborski S. Genetic clues to the pathogenesis of parkinson’s disease. Nat Med. 2004;10(Suppl):S58–S62. doi:10.1038/nm106815272270
   PubMed Web of Science ®Google Scholar
• Taniguchi R, Tan-no K. Combined low calcium and lack magnesium is a risk factor for motor deficit in mice. Biosci Biotechnol Biochem. 2013;77(2):4. doi:10.1271/bbb.120671
   Web of Science ®Google Scholar
• Li Y, Jiao Q, Xu H. Biometal dyshomeostasis and toxic metal accumulations in the development of alzheimer’s disease. Front Mol Neurosci. 2017. doi:10.3389/fnmol.2017.00339
   Web of Science ®Google Scholar
• Oyanagi K, Hashimoto T. Magnesium in Parkinson’s Disease: An Update in Clinical and Basic Aspects. South Australia: University of Adelaid Press; 2011.
   Google Scholar
• Muroyama A, Inaka M, Matsushima H, Sugino H, Marunaka Y, Mitsumoto Y. Enhanced susceptibility to MPTP neurotoxicity in magnesium-deficient C57BL/6N mice. Neurosci Res. 2009;63(1):72–75. doi:10.1016/j.neures.2008.09.00918977253
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Nishi K, Nagasao J, et al. Magnesium exerts both preventive and ameliorating effects in an in vitro rat parkinson disease model involving 1-methyl-4-phenylpyridinium (MPP+) toxicity in dopaminergic neurons. Brain Res. 2008;1197(p):9. doi:10.1016/j.brainres.2007.12.033
   Web of Science ®Google Scholar
• Shindo Y, Yamanaka R, Suzuki K, Hotta K, Oka K. Intracellular magnesium level determines cell viability in the MPP+ model of parkinson’s disease. Biochim Biophys Acta Mol Cell Res. 2015;1853(12):3182–3191. doi:10.1016/j.bbamcr.2015.08.013
   Web of Science ®Google Scholar
• Bennet L, Galinsky R, Draghi V, et al. Time and sex dependent effects of magnesium sulphate on post‐asphyxial seizures in preterm fetal sheep. J Physiol. 2018;596(23):6079–6092. doi:10.1113/tjp.2018.596.issue-2329572829
   PubMed Web of Science ®Google Scholar
• Saver JL, Starkman S, Eckstein M, et al. Methodology of the Field Administration of Stroke Therapy–Magnesium (FAST-MAG) phase 3 trial: part 2–prehospital study methods. Int J Stroke. 2014;9(2):220–225. doi:10.1111/ijs.1224224444117
   PubMed Web of Science ®Google Scholar
• Huang Y, Huang X, Zhang L, et al. Magnesium boosts the memory restorative effect of environmental enrichment in alzheimer’s disease mice. CNS Neurosci Ther. 2018;24(1):70–79. doi:10.1111/cns.2018.24.issue-129125684
   PubMed Web of Science ®Google Scholar
• Zhu H-D, Martin R, Meloni B, et al. Magnesium sulfate fails to reduce infarct volume following transient focal cerebral ischemia in rats. Neurosci Res. 2004;49(3):347–353. doi:10.1016/j.neures.2004.04.00115196783
   PubMed Web of Science ®Google Scholar
• Reddy D, Fallah A, Petropoulos J-A, Farrokhyar F, Macdonald RL, Jichici D. Prophylactic magnesium sulfate for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care. 2014;21(2):356–364. doi:10.1007/s12028-014-9964-024619389
   PubMed Web of Science ®Google Scholar
• Saver JL, Starkman S, Eckstein M, et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372(6):528–536. doi:10.1056/NEJMoa140882725651247
   PubMed Web of Science ®Google Scholar
• Huenges Wajer I, Dorhout Mees S, van den Bergh W, et al. Effect of magnesium on cognition after aneurysmal subarachnoid haemorrhage in a randomized trial. Eur J Neurol. 2018;25(12):1486–1489. doi:10.1111/ene.2018.25.issue-1230048027
   PubMed Web of Science ®Google Scholar
• Sun L, Kosugi Y, Kawakami E, Piao YS, Hashimoto T, Oyanagi K. Magnesium concentration in the cerebrospinal fluid of mice and its response to changes in serum magnesium concentration. Magnes Res. 2009;22(4):266–272. doi:10.1684/mrh.2009.018620228005
   PubMed Web of Science ®Google Scholar
• Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010;65(2):165–177. doi:10.1016/j.neuron.2009.12.02620152124
   PubMed Web of Science ®Google Scholar
• Li W, Yu J, Liu Y, et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model. Mol Brain. 2014;7:65. doi:10.1186/s13041-014-0065-y25213836
   PubMed Web of Science ®Google Scholar
• Sadir S, Tabassum S, Emad S, et al. Neurobehavioral and biochemical effects of magnesium chloride (MgCl 2), magnesium sulphate (MgSO 4) and magnesium-L-threonate (MgT) supplementation in rats: a dose dependent comparative study. Pak J Pharm Sci. 2019;32.
   Web of Science ®Google Scholar
• Gil-Martinez AL, Cuenca L, Sanchez C, Estrada C, Fernandez-Villalba E, Herrero MT. Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential? J Neuroinflammation. 2018;15(1):328. doi:10.1186/s12974-018-1357-430477535
   PubMed Web of Science ®Google Scholar
• Council NR. Guide for the Care and Use of Laboratory Animals. National Academies Press; 2010.
   Google Scholar
• Li Y, Jiao Q, Du X, et al. Investigation of behavioral dysfunctions induced by monoamine depletions in a mouse model of parkinson’s disease. Front Cell Neurosci. 2018;12:241. doi:10.3389/fncel.2018.0024130135645
   PubMed Web of Science ®Google Scholar
• Miyanishi KC, Mohammed E, Watanabe M, Kubo M. Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson’s disease model. Neurochem Int. 2019;122:8. doi:10.1016/j.neuint.2018.11.00530336179
   PubMed Web of Science ®Google Scholar
• Rozas G. The overall rod performance test in the MPTP-treated-mouse model of parkinsonism. J Neurosci Methods. 1998;83(2):10. doi:10.1016/S0165-0270(98)00078-8
   Web of Science ®Google Scholar
• Westermaier T, Stetter C, Kunze E, et al. Magnesium treatment for neuroprotection in ischemic diseases of the brain. Exp Transl Stroke Med. 2013;5(1):6. doi:10.1186/2040-7378-5-623618347
   PubMedGoogle Scholar
• Lingam I, Meehan C, Avdic-Belltheus A, et al. Short-term effects of early initiation of magnesium infusion combined with cooling after hypoxia-ischemia in term piglets. Pediatr Res. 2019.
   Web of Science ®Google Scholar
• Gee JN. Hypermagnesemia does not increase brain intracellular magnesium in newborn swine. Pediatr Neurol. 2001;25(4):4. doi:10.1016/S0887-8994(01)00317-4
   Web of Science ®Google Scholar
• Pamphlett R. Magnesium supplementation does not delay disease onset or increase survival in a mouse model of familial ALS. J Neurol Sci. 2003;216(1):3. doi:10.1016/S0022-510X(03)00216-8
   Web of Science ®Google Scholar
• Sen AP, Gulati A. Use of magnesium in traumatic brain injury. Neurotherapeutics. 2010;7(1):91–99. doi:10.1016/j.nurt.2009.10.01420129501
   PubMed Web of Science ®Google Scholar
• McKee JA. Magnesium neuroprotection is limited in humans with acute brain injury. Neurocrit Care. 2005;2(3):9. doi:10.1385/NCC:2:3:342
   Web of Science ®Google Scholar
• Euser AG, Cipolla MJ. Magnesium sulfate for the treatment of eclampsia: a brief review. Stroke. 2009;40(4):1169–1175. doi:10.1161/STROKEAHA.108.52778819211496
   PubMed Web of Science ®Google Scholar
• Wenwen X, Jing Y, Yingchao S, Qinglu W. The effect of magnesium deficiency on neurological disorders: a narrative review article. Iran J Public Health. 2019;48(3):379.31223564
   PubMed Web of Science ®Google Scholar
• Li W, Yu J, Liu Y, et al. Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer’s disease mouse model. Soc Neurosci. 2013;7:65.
   Google Scholar
• Oyanagi K, Kawakami E, Kikuchi-Horie K, et al. Magnesium deficiency over generations in rats with special references to the pathogenesis of the parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Neuropathology. 2006;26(2):115–128. doi:10.1111/neu.2006.26.issue-216708544
   PubMed Web of Science ®Google Scholar
• Mazur A, Maier JA, Rock E, Gueux E, Nowacki W, Rayssiguier Y. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys. 2007;458(1):48–56. doi:10.1016/j.abb.2006.03.03116712775
   PubMed Web of Science ®Google Scholar
• Kharitonova M, Iezhitsa I, Zheltova A, Ozerov A, Spasov A, Skalny A. Comparative angioprotective effects of magnesium compounds. J Trace Elem Med Biol. 2015;29:227–234. doi:10.1016/j.jtemb.2014.06.02625127069
   PubMed Web of Science ®Google Scholar
• Wolf FI, Trapani V, Simonacci M, Ferré S, Maier JA. Magnesium deficiency and endothelial dysfunction: is oxidative stress involved? Magnesium Res. 2008;21(1):58–64.
   PubMed Web of Science ®Google Scholar
• López A. Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthases. PLoS One. 2017;12(8):e0183090. doi:10.1371/journal.pone.018309028800639
   PubMed Web of Science ®Google Scholar
• Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson’s disease. Neuroscience. 2015;302:89–102.25450953
   PubMed Web of Science ®Google Scholar
• Kurosaki H, Yamaguchi K, Man-yoshi K, Muramatsu S-I, Hara S, Ichinose H. Administration of tetrahydrobiopterin restored the decline of dopamine in the striatum induced by an acute action of MPTP. Neurochem Int. 2019;125:16–24. doi:10.1016/j.neuint.2019.02.00530739038
   PubMed Web of Science ®Google Scholar
• Aras S, Tanriover G, Aslan M, Yargicoglu P, Agar A. The role of nitric oxide on visual-evoked potentials in MPTP-induced parkinsonism in mice. Neurochem Int. 2014;72:48–57. doi:10.1016/j.neuint.2014.04.01424795109
   PubMed Web of Science ®Google Scholar
• Wu DC. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of parkinson disease. J Neurosci Methods. 2002;22(5):8.
   Google Scholar
• Kim HG, Ju MS, Ha SK, et al. Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo. Biol Pharm Bull. 2012;35(8):1287–1294. doi:10.1248/bpb.b12-0012722863927
   PubMed Web of Science ®Google Scholar
• Hammond SL. The Nurr1 Ligand,1,1-bis(3ʹ-Indolyl)-1-(p-Chlorophenyl)methane, modulates glial reactivity and is neuroprotective in MPTP-induced parkinsonism. J Pharmacol Exp Ther. 2018;365(3):15. doi:10.1124/jpet.117.246389
   Web of Science ®Google Scholar
• Jiang L. Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase. J Neuroinflammation. 2016;13(1). doi:10.1186/s12974-016-0573-z
   Web of Science ®Google Scholar
• Barbagallo M, Belvedere M, Sprini D, Dominguez LJ. Magnesium and alzheimer’s disease: implications for diet and nutrition In:  Martin CR, Preedy VR, editors. Diet and Nutrition in Dementia and Cognitive Decline. Elsevier; 2015:585–592.
   Google Scholar
• Wang Q, Zhang H, Liu M, et al. [P38 MAPK signaling pathway regulates nuclear factor-kappaB and inducible nitric oxide synthase expressions in the substantia nigra in a mouse model of parkinson’s disease]. Nan Fang Yi Ke Da Xue Xue Bao. 2014;34(8):1176–1180.25176090
   PubMedGoogle Scholar
• Ghosh A, Kanthasamy A, Joseph J, et al. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of parkinson’s disease. J Neuroinflammation. 2012;9:241. doi:10.1186/1742-2094-9-24123092448
   PubMed Web of Science ®Google Scholar
• Tariq M, Khan HA, al Moutaery K, al Deeb SM. Effect of chronic administration of magnesium sulfate on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Pharmacol Toxicol. 1998;82(5):218–222. doi:10.1111/j.1600-0773.1998.tb01428.x9646326
   PubMedGoogle Scholar
• Erro R, Pappatà S, Amboni M, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2012;18(9):1034–1038. doi:10.1016/j.parkreldis.2012.05.02222789824
   PubMed Web of Science ®Google Scholar
• Wood SJ, Toth M. Molecular pathways of anxiety revealed by knockout mice. Mol Neurobiol. 2001;23(2–3):101–119. doi:10.1385/MN:23:2-3:10111817214
   PubMed Web of Science ®Google Scholar
• Vuckovic MG, Wood RI, Holschneider DP, et al. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis. 2008;32(2):319–327. doi:10.1016/j.nbd.2008.07.01518718537
   PubMed Web of Science ®Google Scholar